Membranous Nephropathy

  • Peter W. Mathieson


Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome in adults: recent figures from the Netherlands show an incidence of around ten per million population per year [1]. Identical clinical presentation and histological appearances can occur whether the condition is primary or ‘idiopathic’ (IMN) or when it is secondary to various drugs, infections or tumours (see Table 17.1), so that careful consideration to exclude an underlying cause is needed when assessing each new patient. When such a cause can be identified, the prognosis is that of the underlying condition and management should be directed towards that condition: causative drugs should be stopped and infections or tumours treated and eradicated if possible. If successful the secondary MN can be expected to resolve.


Nephrotic Syndrome Membranous Nephropathy Spontaneous Remission Renal Vein Thrombosis Membranous Glomerulonephritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hofstra JM, Wetzels JFM. Introduction of a cyclophosphamide-based strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands. Nephrol Dial Transplant. 2008;23:3534–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Ponticelli C. Membranous nephropathy. J Nephrol. 2007;20(3):268–87.Google Scholar
  3. 3.
    Lien YH, Lai LW. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 2011;7(2):85–95.Google Scholar
  4. 4.
    Beck LH Jr. Membranous nephropathy and malignancy. Semin Nephrol. 2010;30(6):635–44.Google Scholar
  5. 5.
    Mathieson PW. Membranous nephropathy. Br J Ren Med. 2002;7:17–20.Google Scholar
  6. 6.
    Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010;56:157–67.PubMedCrossRefGoogle Scholar
  7. 7.
    Cybulsky AV. Membranous nephropathy. Contrib Nephrol. 2011;169:107–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet. 2004;364:1252–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Beck Jr LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364:689–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Qin W, Beck Jr LH, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22:1137–43.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Cravedi P, Ruggenenti P, Remuzzi G. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. J Am Soc Nephrol. 2011;22:1400–2.PubMedCrossRefGoogle Scholar
  13. 13.
    Beck Jr LH, Salant DJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int. 2010;77:765–70.PubMedCrossRefGoogle Scholar
  14. 14.
    Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364:616–26.PubMedCrossRefGoogle Scholar
  15. 15.
    Makker SP, Tramontano A. Idiopathic membranous nephropathy: an autoimmune disease. Semin Nephrol. 2011;31:333–40.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin Nephrol. 2003;23(4):406–11.Google Scholar
  17. 17.
    Barbour SJ, Greenwald A. Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81(2):190–5.Google Scholar
  18. 18.
    Polanco N, Gutierrez E. Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704.Google Scholar
  19. 19.
    KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int Suppl. 2012;2(2):187–97.Google Scholar
  20. 20.
    Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007;18(8):2221–5.Google Scholar
  21. 21.
    Schieppati A, Perna A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2004;(4):CD004293.Google Scholar
  22. 22.
    Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48:1600–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9:444–50.PubMedGoogle Scholar
  24. 24.
    Howman A, et al. The UK randomised controlled trial of immunosuppression for progressive membranous nephropathy. Lancet. 2013;381(9868):744–51.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Beck Jr LH, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22:1543–50.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis. 2006;47:233–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64:3043–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Lindskog A, Ebefors K, Johansson ME, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol. 2010;21:1290–8.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Ivanyi B. A primer on recurrent and de novo glomerulonephritis in renal allografts. Nat Clin Pract Nephrol. 2008;4(8):446–57.Google Scholar
  30. 30.
    Sprangers B, Lefkowitz GI, Cohen SD, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol. 2010;5(5):790–7.Google Scholar
  31. 31.
    Reichert LJ, Koene RA, Wetzels JF. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis. 1998;31(1):1–11.Google Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Academic Renal UnitUniversity of Bristol and Southmead HospitalBristolUK

Personalised recommendations